ArticleFrontiers in oncology2025
Efficacy and survival analysis of neoadjuvant chemotherapy combined with immunotherapy in locally advanced resectable Siewert type II adenocarcinoma of the esophagogastric junction.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemotherapy combined with immunotherapy (nCI) has achieved significant results in esophageal and gastric cancers, but its efficacy in Siewert type II adenocarcinoma of the esophagogastric junction (AEG) remains unclear. This study aims to verify the efficacy and safety of nCI in real-world settings for locally advanced resectable Siewert type II AEG. Methods: A retrospective analysis of clinical data from 101 patients with locally advanced resectable Siewert type IIAEG who underwent esophagogastric junction resection after chemotherapy combined with Sintilimab in a single-center treatment group from December 2020 to May 2024. The analysis focused on the rates of pathological complete response (pCR), major pathological response (MPR), R0 resection rate, tumor downstaging, recurrence-free survival (RFS), and safety. Results: A total of 101 patients were included, the median follow-up time was 19.2 months. 74 patients (73.3%) experienced postoperative pathological downstaging, with 78 patients (77.2%) showing postoperative pathological T downstaging and 47 patients (55.3%) showing postoperative pathological N downstaging. Patients with cT3 had better outcomes in pCR, MPR, and postoperative pathological downstaging compared to those with cT4 (pCR 27.9% vs 12.1% p=0.044, MPR 48.8% vs 25.9% p=0.017, postoperative pathological downstaging rate 83.7% vs 65.5% p=0.041). 3-4 cycles of nCI yield a higher pathological complete response (pCR) rate compared to 1-2 cycles (26.7% vs 7.3%, Conclusion: Preliminary results indicate that nCI shows promising efficacy in the treatment of resectable locally advanced Siewert type II AEG, with high rates of pCR and MPR, as well as good tolerance and safety. 3-4 cycles of nCI may provide better therapeutic efficacy than 1-2 cycles. These findings require confirmation in prospective head-to-head trials to establish potential long-term clinical benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.